Probiotic bacteria lactobacillus and bifidobacterium attenuate inflammation in dextran sulfate sodium-induced experimental colitis in mice

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue 4, 2014, Pages 615-627

  Toumi, R ^a   Soufli, I ^a   Rafa, H ^a   Belkhelfa, M ^a   Biad, A ^b   Touil Boukoffa, C ^a  

^a UNIVERSITY OF SCIENCES AND TECHNOLOGY HOUARI BOUMEDIENE   (Algeria)

^b CHU d'Aïn Taya   (Algeria)

Author keywords

Experimental colitis; Inflammatory bowel disease; Nitric oxide; Probiotics; Therapeutic approaches

Indexed keywords

DEXTRAN SULFATE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRITE; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 4; NOS2 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM BREVE; BLEEDING; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DESCENDING COLON; DIARRHEA; DISEASE ACTIVITY SCORE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIZATION; EXPERIMENTAL COLITIS; EXPLANT; FEMALE; GENE OVEREXPRESSION; GOBLET CELL; HISTOLOGY; IMMUNOFLUORESCENCE TEST; INFLAMMATORY CELL; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS DELBRUECKII SUBSP. LACTIS; LACTOBACILLUS PLANTARUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BIFIDOBACTERIUM; BIOSYNTHESIS; CHEMICALLY INDUCED; COLITIS; GENETICS; LACTOBACILLUS; PHYSIOLOGY;

ANIMALS; BIFIDOBACTERIUM; COLITIS; DEXTRAN SULFATE; FEMALE; INTERFERON-GAMMA; LACTOBACILLUS; MICE; MICE, INBRED BALB C; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROBIOTICS; TOLL-LIKE RECEPTOR 4;

EID: 84925230968     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201402700418     Document Type: Article

References (30)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-29.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448:427-34.
3. Macpherson A J, Harri NL. Interactions between commensal intestinal bacteria and the immune system. Nature Rev Immunol 2004; 4:478-85.
4. Rakoff-Nahoum S, Medzhitov R. Innate immune recognition of the indigenous microbial flora. Mucosal Immunol 2008;1(S):10-14.
5. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68:7010-17.
6. Ortega-Cava CF, Ishihara S, Rumi MA, et al. Strategic compart mentalization of Toll-like receptor 4 in the mouse gut. J Immunol 2003; 170:3977-85.
7. Rachmilewitz D, Stamler JS, Bachwich D, et al. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 1995; 36:718-23.
8. Obermeier F, Kojouharoff G, Hans W, Scholmerich J, Gross V, Falk W. Interferon gamma (IFN- γ) and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol 1999; 116:238-45.
9. Abdelouhab K, Rafa H, Toumi R, Bouaziz S, Medjeber O, Touil-Boukoffa C. Mucosal intestinal alteration in experimental colitis correlates with nitric oxide production by peritoneal macrophages: Effect of probiotics and prebiotics. Immunopharmac Immunotoxicol 2011; 34:590-97.
10. Toumi R, Abdelouhab K, Rafa H, Soufli I, Raissi- Kerboua D, Djeraba Z, Touil-Boukoffa C. Beneficial role of the probiotic mixture Ultrabiotique on maintaining the integrity of intestinal mucosal barrier in DSS-induced experimental colitis. Immunopharmacol Immunotoxicol 2013; 35:403-9.
11. Rafa H, Saoula H, Belkhelfa M, et al. IL-23/IL- 17 Axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retoinic acid. J Interferon Cytokine Res 2013;37(3) 355-68.
12. Kolios G, Rooney N, Murphy CT, Robertson DAF, Westwick J. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: modulation by T-lymphocyte derived cytokines. Gut 1998; 43:56-63.
13. Podolskiy DK. Inflammatory bowel disease. N Engl J Med 2002; 347 417-29.
14. Food and Agriculture Organization of the United Nations and World Health Organization (FAO/WHO). Guidelines for the evaluation of probiotics in food; 2002.
15. Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis 2008; 14:1585-96.
16. Murthy SNS, Cooper HS, Shim H, et al. Treatment of dextran sulfate sodium-induced murine colitis by in- tracolonic cyclosporin. Dig Dis Sci 1993; 38:1722-34.
17. Siegmund B, Fantuzzi G, Rieder F, et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN- γ and TNF-α production. Am J Physiol 2001; 281:1264-73.
18. Touil-boukoffa C, Sanceau J, Tayebi B, Wietzerbin J. Relationship among circulating interferon, tumor necrosis factor-α, and interleukin-6 and serologic reaction against parasitic antigen in human hydatidosis. J Interferon Cytokine Res 2007; 17: 211-17.
19. Saura M, Zaragoza C, Clare Bao, McMillan A, Lowenstein CJ. Interaction of interferon regulatory factor-1 and nuclear factor kB during activation of inducible nitri oxide synthase transcription. J Mol Biol 1999; 289:459-71.
20. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacte- riotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305-9.
21. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69:238-49.
22. Benight NM, Stoll B. Marini JC. Burrin DG. Preventative oral methylthioadenosine is anti-inflammatory and reduces DSS-induced colitis in mice. Am J Physiol Gastrointest Liver Physiol 2012; 303:G71-G82.
23. Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 1995;36:718-23.
24. Ito R, Shin-Ya M, Kishida T, et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol 2006; 146:330-38.
25. Abreu MT, Arnold ET, Thomas LS, Gonsky R, Zhou Y, Hu B, Arditi M. TLR4 and MD-2 expres-sion is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem 2002; 277:20431-37.
26. Giahi L, Aumueller, Elmadfa I, Haslberger AG. Regulation of TLR4, p38 MAPkinase, IκB and miR- NAs by inactivated strains of lactobacilli in human dendritic cells. Benef Microbes 2012; 3(2):91-98.
27. Di-Giacinto C, Marinaro M, Sanchez M, Strober W, Boirvant M. Probiotics ameliorate recurrent Th-1 mediated murine colitis by inducing IL-10 and IL-10 dependent TGF-b bearing regulatory cells. J Immunol 2005; 174:3237-46.
28. Fitzpatrick LR, Jeffrey S, Hoerr RA, Bostwick EF, Maines L, Koltun WA. In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: immu- nomodulation and attenuation of murine colitis. Br J Nutr 2008; 100:530-41.
29. Schottelius AJG, Baldwin Jr AS. A role for transcription factor NF-kB in intestinal inflammation. Int J Colorectal Dis 1999; 14:18-28.
30. Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AGP, Pettersson S, Conway S. Commen- sal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR- γ and RelA. Nature Immunol 2004; 5:104-12.